Comparing stem cell transplant vs more chemo for high-risk AML
Part of Blood & lymphatic, Cancer clinical trials.
This study compares two treatment approaches for people with high-risk acute myeloid leukemia (AML) that did not go away after one round of chemotherapy: an immediate stem cell transplant (from a donor) versus another round of chemotherapy. The goal is to see which strategy leads to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high-risk acute myeloid leukemia (AML) based on 2022 ELN guidelines.
- You have received one round of induction chemotherapy.
- You are able to have a stem cell transplant from a donor (either related or unrelated).
- Your performance status (KPS) is above 60, meaning you can do most daily activities.
- You have not had a stem cell transplant before.
- You are not pregnant or breastfeeding, and do not have active leukemia in your spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.